Targanta's Oritavancin Gets "Complete Response": Another Phase III Needed
• By Carlene Olsen
FDA threw Targanta a curveball in issuing a "complete response" letter Dec. 8, requiring an additional Phase III study for its complicated skin and skin structure infection treatment oritavancin before approval
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Stefan Oelrich, the newly-announced president of European pharma industry federation EFPIA says the EU pharma reform is “not an improvement on the status quo” in its current form.
Oncology trial sponsors in the UK are being invited to participate in a pilot that aims to tackle duplication and variation in pharmacy reviews, which are an important part of setting up clinical trials in the National Health Service.
The new Advisory Committee on Immunization Practices voted for new recommendations on the decades-old thimerosal safety issue and lays intellectual groundwork to revisit other past controversies and decisions.